NTX-1088 is a humanised monoclonal antibody targeting PVR/CD155, which blocks the interaction between PVR and the co-stimulatory receptor DNAM1/CD226. It induces DNAM1 recovery and immune activation, making it suitable for anti-tumour immunotherapy.
Purity:
95.00%
Target:
Immunology/Inflammation related
T9901A-511
* VAT and and shipping costs not included. Errors and price changes excepted
